35Pharma to Present Preclinical Results with HS135, a Novel Activin and GDF Ligand Trap for Cardiopulmonary Disease, at the ERS International Congress 2022

Montreal, QC, Canada (Aug. 26, 2022) – 35Pharma, a biopharmaceutical company that designs and develops biologics for cardiopulmonary diseases, announced today that it will present preclinical results from its HS135 program at the European Respiratory Society (“ERS”) International Congress 2022 which will be held in-person and virtually in Barcelona, Spain (Sept. 4 – 6, 2022).

Details of the presentation are as follows:

HS135: Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension (PH)

Abstract #35129
Poster: PA4146
Session: Basic science in pulmonary hypertension

Date: Tuesday, Sept. 6, 2022
Time: 1:00 – 2:00 PM CEST
Location: Thematic Poster Area at FIRA Barcelona Gran VIA congress centre (Barcelona, Spain)

The abstract was posted to the ERS Congress website.

About 35Pharma and HS135
35Pharma is a biopharmaceutical company that designs and develops best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for cardio-pulmonary and -metabolic diseases. HS135 is a multi-specific receptor ectodomain ligand trap designed to achieve maximum neutralization of Activins & GDFs, clinically validated drivers of cardio-pulmonary and -metabolic disease. HS135 is undergoing preclinical development and is projected to enter human clinical trials in 2023.

Contact
Julia Schoelermann, VP Business Development, 35Pharma
info@35pharma.com

For more information, please visit www.35pharma.com